670 Long-term results of interstin therapy for voiding disorders demonstrate sustained efficacy and acceptable safety profile

Kerrebroeck, P. Van; Voskuilen, A. Van; Lycklama, A.; Nÿeholt, A.A.B. Lycklama à; Dijkema, H.E.; Bemelmans, Bart L.H.; Fall, Maouly; Fowler, Clare J.; Das, Anindya; Milam, Douglas F.; Siegel, Steven; Hombergh, Ubi van den

doi:10.1016/s1569-9056(04)90665-3

Cited by 9 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, an important finding in this study is the high correlation between the 1- and 5-year success rates. Of the implanted patients, 84% with UI, 71% with UF, and 78% with retention continued to have a successful outcome at 5-year follow-up if successful at 1 year [46]. Different clinics have published their long-term results in the previous years [47–49].…”

Section: Clinical Results and Complications Of Snsmentioning

confidence: 99%

Long-term results of vaginal repairs with and without xenograft reinforcement

2009

View full text Add to dashboard Cite

Sacral neuromodulation has been developed to treat chronic lower urinary tract symptoms, resistant to classical conservative therapy. The suspected mechanisms of action include afferent stimulation of the central nervous system and modulation of activity at the level of the brain. Typical neuromodulation is indicated both in overactivity and in underactivity of the lower urinary tract. In the majority of patients, a unilateral electrode in a sacral foramen and connected to a pulse generator is sufficient to achieve significant clinical results also on long term. In recent years, other urological indications have been explored.

show abstract

Section: Clinical Results and Complications Of Snsmentioning

confidence: 99%

Long-term results of vaginal repairs with and without xenograft reinforcement

2009

View full text Add to dashboard Cite

show abstract

“…In the longer term, intravesical resiniferatoxin was inferior to botulinum toxin (BTX) in urodynamic results and clinical benefits for patients with NDO [8]. Sacral neuromodulation can have major benefits in cases of urge incontinence [9], but results are disappointing when there is a neurogenic lesion [10]. Surgical treatments, e.g.…”

Section: Introductionmentioning

confidence: 99%

Botulinum toxin‐type A in the treatment of drug‐resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury

Patki¹,

Hamid²,

Arumugam³

et al. 2006

BJU International

View full text Add to dashboard Cite

In this section, many different issues are written about by authors from the UK, France, the Netherlands, the USA and Denmark, respectively. Topics covered are botulinum toxin in drug‐resistant neurogenic detrusor overactivity in spinal cord injury, dutasteride and BPH, the effect of childbirth on bothersome LUTS, female urethral strictures, and a new bulking agent in treating female stress urinary incontinence. OBJECTIVES To assess, in a prospective study, whether botulinum toxin‐type A (BTX‐A) injected into the detrusor muscle, can be used as a day‐case treatment for drug‐resistant neurogenic detrusor overactivity (NDO) in patients with spinal cord injury (SCI). PATIENTS AND METHODS BTX‐A (Dysport, Ipsen, Luxembourg; 1000 units) was injected cystoscopically into the detrusor muscle of 37 patients with drug‐resistant NDO and SCI, as a day‐case procedure. The maximum cystometric capacity (MCC), maximum detrusor pressure (MDP), NDO, continence, and anticholinergic requirement were used as outcome variables. The International Consultation on Incontinence questionnaire (ICIQ) was used to assess the patient’s quality of life before and after the BTX‐A injection. RESULTS The mean follow‐up was 7 months. The MCC increased from a mean of 259 to 522 mL, and the MDP decreased from a mean of 54 to 24 cmH2O. Incontinence and NDO were abolished in 82% and 76% patients, respectively. In all, 86% of the patients were able to stop or reduce anticholinergics, with a similar proportion of patients scoring favourably on the ICIQ. The mean duration of improvement was 9 months. CONCLUSIONS Injection with BTX‐A is an effective day‐case treatment that bridges the gap between oral and invasive surgical treatment of drug‐resistant NDO in patients with SCI.

show abstract

“…Since its introduction about a decade ago, sacral neuromodulation (SN) is applied in patients with refractory urge incontinence, urgency‐frequency and unobstructive urinary retention [1–5]. Typically, potential candidates are tested with a temporary lead before the implantation of a definitive neuromodulation system is considered.…”

Section: Introductionmentioning

confidence: 99%

Medium‐term experience of sacral neuromodulation by tined lead implantation

et al. 2006

View full text Add to dashboard Cite

RESULTSTen patients had a one-stage and 39 a twostage implant; of the latter group, 31 (80%) had a positive response and eight (21%) did not. In all, 31 patients were included in the follow-up. At the last follow-up, 28 (90%) patients had a > 50% improvement in diary variables and three (10%) did not. In 21 patients with urgency symptoms the mean ( SD ) number of voids decreased from 11.7 (8.9)/day at baseline to 7.3 (3.4)/day ( P = 0.1); the voided volume increased from 160.2 (70.7) mL to 231.1 (119.5) mL ( P = 0.001); and the number of leakages decreased from 9.5 (8.7) to 3.3 (2.2)/day ( P = 0.17). In the 10 patients with retention,

show abstract

670 Long-term results of interstin therapy for voiding disorders demonstrate sustained efficacy and acceptable safety profile

Cited by 9 publications

References 0 publications

Long-term results of vaginal repairs with and without xenograft reinforcement

Long-term results of vaginal repairs with and without xenograft reinforcement

Botulinum toxin‐type A in the treatment of drug‐resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury

Medium‐term experience of sacral neuromodulation by tined lead implantation

Contact Info

Product

Resources

About